Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - AU
The Guardian - AU
National
Natasha May

TGA investigating potential link between diabetes drug Ozempic and reports of gastro-intestinal side effects

Ozempic pens sit on a production line at Novo Nordisk's site in Hillerod
The manufacturer’s product information already contains warnings about diabetes turned weight-loss drug Ozempic, but the TGA says the information may need to be updated. Photograph: Tom Little/Reuters

Australia’s drug regulator is investigating new reports of potential gastro-intestinal side effects of diabetes turned weight-loss drug Ozempic.

Ozempic, is a drug prescribed as a treatment for type 2 diabetes, but has been widely used off-label for weight loss, causing worldwide shortages, including in Australia. The same drug, branded as Wegovy, is now approved for weight management in Australia, but is not currently available.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.